Table 1 Baseline characteristics in HIV-1 infected patients who are antiretroviral-naïve (n = 18) or on lopinavir-based antiretroviral therapy (n = 16)
Parameter | ARV-Naïve group | Lopinavir group | p value |
|---|---|---|---|
Sex female n (%) | 17 (94Â %) | 11 (69Â %) | 0.078 |
Age (years) | 27 (25–32) | 37 (33–41) | <0.0001 |
Total lumefantrine dose (mg/kg) | 49.7 (43.0–52.4) | 46.5 (41.4–51.9) | 0.72 |
Weight (kg) | 58 (55–67) | 62 (56–70) | 0.72 |
Albumin (g/L) | 40 (39–44) | 43 (41.5–44) | 0.14 |
Alkaline phosphatase (U/L) | 57.5 (50–69) | 69.5 (59–88) | 0.09 |
Gamma glutamyltransferase (U/L) | 40 (39–44) | 43 (42–44) | 0.03 |
Alanine transaminase (U/L) | 15 (13–29) | 26 (18–44) | 0.72 |
Aspartate transaminase (U/L) | 22 (14–28) | 19 (17–30) | 0.59 |
Mean corpuscular volume (fL) | 86.7 (85–91) | 100.95 (98–110) | 0.0001 |
Concomitant cotrimoxazole n (%) | 6 (33Â %) | 5 (31Â %) | 1.0 |
CD4+ count (×106/L) | 356 (260–507) | 375 (296–590) | 0.7 |
HIV viral load (copies/mL) | log10 3.76 (3.0–4.1) | <50 copies/μL | 0.0005 |